Codex Stock Analysis

DNAY -  USA Stock  

USD 7.54  1.08  12.53%

Codex Dna price slide over the last few months could raise concerns from investors as the firm it trading at a share price of 7.54 on very low momentum in volume. The company executives were not very successful in positioning the firm resources to exploit market volatility in December. However, diversifying your holdings with Codex Dna or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 7.56. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Codex Dna partners.
Continue to Investing Opportunities.

Codex Stock Analysis 

 
Refresh
The Codex Dna stock analysis report makes it easy to digest most publicly released information about Codex Dna and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Codex Stock analysis module also helps to analyze the Codex Dna price relationship with some important fundamental indicators such as market cap and management efficiency.

Codex Stock Analysis Notes

About 53.0% of the company shares are held by company insiders. The book value of Codex Dna was currently reported as 3.51. The company recorded a loss per share of 2.64. Codex Dna had not issued any dividends in recent years. Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California. Codex Dna operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 133 people. To learn more about Codex Dna call the company at 858 228 4115 or check out https://codexdna.com.

Codex Dna Quarterly Cost of Revenue

1.62 MillionShare

Codex Dna Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Codex Dna's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Codex Dna or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Codex Dna generated a negative expected return over the last 90 days
Codex Dna has high historical volatility and very poor performance
The company reported the previous year's revenue of 9.9 M. Net Loss for the year was (32.05 M) with profit before overhead, payroll, taxes, and interest of 3.62 M.
Codex Dna currently holds about 109.8 M in cash with (28.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.75.
Codex Dna has a frail financial position based on the latest SEC disclosures
Roughly 58.0% of the company shares are held by institutions such as insurance companies
Latest headline from www.nasdaq.com: 3 Biotech Stocks To Watch In 2022 - Nasdaq

Codex Dna Upcoming and Recent Events

Earnings reports are used by Codex Dna to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Codex Dna previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report8th of February 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End8th of February 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Codex Largest EPS Surprises

Earnings surprises can significantly impact Codex Dna's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-11-09
2021-09-30-0.2767-0.34-0.063322 
2021-08-10
2021-06-30-0.355-1.06-0.705198 
View All Earnings Estimates

Codex Dna SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Codex Dna prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Codex Dna investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Codex Dna specific information freely available to individual and institutional investors to make a timely investment decision.
29th of December 2021
Entry into a Material Definitive Agreement
View
22nd of November 2021
Other Events
View
10th of November 2021
Financial Statements and Exhibits. Entry into a Material Definitive Agreement
View
9th of November 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition. Entry into a Material Definitive Agreement
View
16th of September 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
10th of August 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
20th of July 2021
Financial Statements and Exhibits. Changes in Registrant's Certifying Accountant
View
1st of July 2021
Unclassified Corporate Event
View

Codex Dna Thematic Classifications

In addition to having Codex Dna stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Measuring and Control IdeaMeasuring and Control
USA Equities from Measuring and Control industry as classified by Fama & French

Codex Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 283.99 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Codex Dna's market, we take the total number of its shares issued and multiply it by Codex Dna's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Codex Profitablity

Codex Dna's profitability indicators refer to fundamental financial ratios that showcase Codex Dna's ability to generate income relative to its revenue or operating costs. If, let's say, Codex Dna is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Codex Dna's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Codex Dna's profitability requires more research than a typical breakdown of Codex Dna's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Average Assets(0.49) (0.53) 
Return on Average Equity 0.98  0.97 
Return on Invested Capital(1.88) (2.03) 
Return on Sales(2.37) (2.56) 

Management Efficiency

Return on Average Assets is likely to drop to -0.53 in 2022. Return on Average Equity is likely to drop to 0.97 in 2022. Codex Dna Total Assets are fairly stable at the moment as compared to the past year. Codex Dna reported Total Assets of 24.18 Million in 2021. Current Assets is likely to rise to about 18.4 M in 2022, whereas Assets Non Current are likely to drop slightly above 10.8 M in 2022. Codex Dna management efficiency ratios could be used to measure how well codex dna manages its routine affairs as well as how well it operates its assets and liabilities.
Last ReportedProjected for 2022
Book Value per Share(1.53) (1.65) 
Tangible Assets Book Value per Share 1.26  1.41 
Tangible Asset Value18.9 M21.2 M

Technical Drivers

As of the 17th of January 2022, Codex Dna shows the mean deviation of 4.83, and Risk Adjusted Performance of (0.022276). Codex Dna technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze nineteen technical drivers for Codex Dna, which can be compared to its rivals. Please confirm Codex Dna standard deviation, as well as the relationship between the maximum drawdown and expected short fall to decide if Codex Dna is priced correctly, providing market reflects its regular price of 7.54 per share. Given that Codex Dna has jensen alpha of (0.36), we suggest you to validate Codex Dna's prevailing market performance to make sure the company can sustain itself at a future point.

Codex Dna Price Movement Analysis

The output start index for this execution was thirty-five with a total number of output elements of twenty-six. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Codex Dna middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Codex Dna. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target. View also all equity analysis or get more info about bollinger bands overlap studies indicator.

Codex Dna Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Codex Dna insiders, such as employees or executives, is commonly permitted as long as it does not rely on Codex Dna's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Codex Dna insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Nelson Todd Robert over three months ago via Macroaxis 
Codex Dna exotic insider transaction detected
Hunter Brent M over three months ago via Macroaxis 
Acquisition by Hunter Brent M of 5500 shares of Codex Dna subject to Rule 16b-3
Northpond Ventures Gp Ii Llc over six months ago via Macroaxis 
Codex Dna exotic insider transaction detected
Gattaca Mining Llc over six months ago via Macroaxis 
Conversion by Gattaca Mining Llc of 2000000 shares of Codex Dna
Hunter Brent M over six months ago via Macroaxis 
Purchase by Hunter Brent M of 500 shares of Codex Dna

Codex Dna Technical and Predictive Indicators

Codex Dna Forecast Models

Codex Dna time-series forecasting models is one of many Codex Dna's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Codex Dna's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Codex Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Codex Dna stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Codex shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Codex Dna. By using and applying Codex Stock analysis, traders can create a robust methodology for identifying Codex entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin(2.17) (2.34) 
Gross Margin 0.63  0.62 
Profit Margin(2.47) (2.66) 
Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California. Codex Dna operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 133 people.

Current Codex Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Codex analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Codex analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
25.0Strong Buy2Odds
Codex Dna current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Codex analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Codex stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Codex Dna, talking to its executives and customers, or listening to Codex conference calls.
Codex Analyst Advice Details

Codex Stock Analysis Indicators

Codex Dna stock analysis indicators help investors evaluate how Codex Dna stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Codex Dna shares will generate the highest return on investment. By understating and applying Codex Dna stock analysis, traders can identify Codex Dna position entry and exit signals to maximize returns.
Quick Ratio14.34
Fifty Two Week Low6.16
Revenue Growth70.40%
Shares Short Prior Month492.42k
Average Daily Volume Last 10 Day2.67M
Average Daily Volume In Three Month503.63k
Shares Percent Shares Out3.48%
Gross Margins43.79%
Short Percent Of Float18.75%
Forward Price Earnings-6.29
Float Shares7.44M
Fifty Two Week High25.70
Enterprise Value To Ebitda-6.89
Fifty Day Average8.03
Two Hundred Day Average11.80
Enterprise Value To Revenue19.23
Continue to Investing Opportunities. Note that the Codex Dna information on this page should be used as a complementary analysis to other Codex Dna's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Stock Screener module to find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

Complementary Tools for Codex Stock analysis

When running Codex Dna price analysis, check to measure Codex Dna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Codex Dna is operating at the current time. Most of Codex Dna's value examination focuses on studying past and present price action to predict the probability of Codex Dna's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Codex Dna's price. Additionally, you may evaluate how the addition of Codex Dna to your portfolios can decrease your overall portfolio volatility.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Is Codex Dna's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Codex Dna. If investors know Codex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Codex Dna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Codex Dna is measured differently than its book value, which is the value of Codex that is recorded on the company's balance sheet. Investors also form their own opinion of Codex Dna's value that differs from its market value or its book value, called intrinsic value, which is Codex Dna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Codex Dna's market value can be influenced by many factors that don't directly affect Codex Dna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Codex Dna's value and its price as these two are different measures arrived at by different means. Investors typically determine Codex Dna value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Codex Dna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.